Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot"

Affiliations

¹ The Kirby Institute, UNSW Sydney, Sydney, Australia. Electronic address: rwaziry@kirby.unsw.edu.au.
² Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
³ The Kirby Institute, UNSW Sydney, Sydney, Australia.

Comment

Reem Waziry et al. J Hepatol. 2018 Mar.

. 2018 Mar;68(3):616-617.

doi: 10.1016/j.jhep.2017.10.002. Epub 2017 Oct 9.

¹ The Kirby Institute, UNSW Sydney, Sydney, Australia. Electronic address: rwaziry@kirby.unsw.edu.au.
² Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
³ The Kirby Institute, UNSW Sydney, Sydney, Australia.

No abstract available

Comment on

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Waziry R, et al. J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9. J Hepatol. 2017. PMID: 28802876
Direct antiviral agents and risk of HCC: Waiting for Godot.
Cammà C, Leandro G. Cammà C, et al. J Hepatol. 2018 Mar;68(3):614-616. doi: 10.1016/j.jhep.2017.08.039. Epub 2017 Oct 9. J Hepatol. 2018. PMID: 29024699 No abstract available.